Canine parvovirus/CPV/CPV2,/parvo VP2 antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Canine parvovirus/CPV/CPV2,/parvo VP2 antibodies pairs and antigen for animal health (animal Dog/Canine infectious disease Canine parvovirus infection) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Companion Animal disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P030-Tg001-Ag01	Recombinant Canine parvovirus/CPV/CPV2,/parvo VP2 protein	$3090.00
GMP-VT-P030-Tg001-Ab01	Anti-Canine parvovirus/CPV/CPV2,/parvo VP2 mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P030-Tg001-Ab02	Anti-Canine parvovirus/CPV/CPV2,/parvo VP2 mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P030-Tg001-Ab03	Anti-Canine parvovirus/CPV/CPV2,/parvo VP2 human monoclonal antibody (mAb)	$3090.00
GMP-VT-P030-Tg001-Ab04	Anti-Canine parvovirus/CPV/CPV2,/parvo VP2 human monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P030-Tg001-Ag01
Product Name	Recombinant Canine parvovirus/CPV/CPV2,/parvo VP2 protein
Pathogen	Canine parvovirus/CPV/CPV2,/parvo
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Canine parvovirus/CPV/CPV2,/parvo VP2 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Canine parvovirus/CPV/CPV2,/parvo level test of animal Dog/Canine infectious disease with Canine parvovirus infection.
Tag	His
Product description	Recombinant Canine parvovirus/CPV/CPV2,/parvo VP2 proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P030-Tg001-Ab01,GMP-VT-P030-Tg001-Ab02
Pathogen	Canine parvovirus/CPV/CPV2,/parvo
Product Name	Anti-Canine parvovirus/CPV/CPV2,/parvo VP2 mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Canine parvovirus/CPV/CPV2,/parvo VP2 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Canine parvovirus/CPV/CPV2,/parvo antibodies in Canine parvovirus/CPV/CPV2,/parvo level test of animal Dog/Canine infectious disease with Canine parvovirus infection.
Product description	Anti-Canine parvovirus/CPV/CPV2,/parvo VP2 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Canine parvovirus/CPV/CPV2,/parvo antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P030-Tg001-Ab03,GMP-VT-P030-Tg001-Ab04
Pathogen	Canine parvovirus/CPV/CPV2,/parvo
Product Name	Anti-Canine parvovirus/CPV/CPV2,/parvo VP2 human monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Recombinant Canine parvovirus/CPV/CPV2,/parvo VP2 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Canine parvovirus/CPV/CPV2,/parvo antibodies in Canine parvovirus/CPV/CPV2,/parvo level test of animal Dog/Canine infectious disease with Canine parvovirus infection.
Product description	Anti-Canine parvovirus/CPV/CPV2,/parvo VP2 mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen Information

Canine parvovirus (CPV) is a highly infectious pathogen that affects dogs worldwide. The virus primarily targets rapidly dividing cells in the intestinal lining and bone marrow, leading to a range of diseases.

CPV is a single-stranded DNA virus that belongs to the Parvoviridae family. It is non-enveloped and has a small, icosahedral capsid. The virus is highly resistant to environmental factors, such as heat and disinfectants, making it challenging to control.

The virus is transmitted through the fecal-oral route, meaning that infected dogs shed the virus in their feces, which can contaminate the environment. Susceptible dogs become infected when they ingest the virus through contaminated food, water, or objects.

CPV primarily infects dogs, particularly puppies under six months of age who have not yet completed their vaccination series. However, adult dogs can also become infected if they have not been properly vaccinated. Certain dog breeds, such as American Staffordshire Terriers, Rottweilers, and Doberman Pinschers, may be more susceptible to CPV infection than others.

Once inside a host cell, CPV replicates and produces viral progeny, which are released into the bloodstream and can infect other tissues in the body. The virus targets rapidly dividing cells, such as those in the bone marrow and intestinal lining, leading to cell death and tissue damage.

The most common clinical signs of CPV infection include lethargy, vomiting, diarrhea (often bloody), and fever. In severe cases, dehydration, sepsis, and shock can occur, which can be life-threatening if left untreated.

Diagnosis of CPV infection is typically done through a combination of clinical signs, history, and laboratory tests. Antigen detection tests, such as ELISA, can detect the presence of CPV in fecal samples. Viral isolation involves culturing the virus from a sample and may take several days to produce results. Nucleic acid tests, such as polymerase chain reaction (PCR), detect the virus's DNA and are highly sensitive and specific. PCR tests typically target the VP2 gene, which is highly conserved among CPV strains. Other genes, such as NS1 and NS2, may be targeted in some diagnostic methods.

Treatment of CPV infection primarily involves supportive care, such as fluid therapy and antiemetic medication, to manage clinical signs and prevent dehydration. Antibiotics may be prescribed to treat secondary bacterial infections. Severely affected dogs may require hospitalization and intensive care.

Prevention of CPV infection involves proper vaccination of dogs. Puppies should receive a series of vaccinations starting at 6-8 weeks of age and continuing every 3-4 weeks until they are 16-20 weeks old. Adult dogs should be revaccinated every 1-3 years, depending on their risk of exposure. Good hygiene practices, such as regular cleaning and disinfection of environments where dogs are housed, can also help to prevent the spread of the virus.

In conclusion, CPV is a serious pathogen that can cause significant morbidity and mortality in dogs, particularly in puppies and unvaccinated dogs. Proper prevention and control measures are essential to reduce the incidence and impact of CPV infection.

About GDU